randomized trial of combined chemotherapy including highdose cisplatin and radiotherapy for nasopharyngeal carcinoma

A prospective randomized trial in 88 nasopharyngeal carcinoma patients was conducted from 1989 to 1990 The patients were randomized into two groups, (HD-DDP+UFT) regimen plus ra-diotherapy (combined group) or radiotherapy alone. (control group). The 1-，3-year survival rates in overall groups were 84. 1% (74/88) and 46. 6% (42/88). The 1-year survival rates in the combined and control groups were 86. 7% (39/45) and 81. 4% (35/43) (P>0.05). The 3 -year survival rates were5l. 1% (23/45) and 41. 9% (18/43)，respectively (P>0. 05). Our pre-liminary results show that combined chemotherapy including highdose cisplatin and radiotherapy may improve the therapeutic result of nasopharyngeal carcinoma.